Local therapy, such as radiotherapy, targeting oligo-progressive tumor lesions in patients with AR or acquired resistance may improve patient survival as it could effectively eradicate tumor lesions compromising PD1/PD-L1-inhibitor-resistant subclones and enhance the systemic antitumor immune response through synergistic effects between radiotherapy and immunotherapy [38,39,40]. Here, CD274 is linked to neoplasm.